SIM0270
- Generic Name
- SIM0270
A Study of SIM0270 Combined with Everolimus Vs. Treatment of Physician's Choice in Patients with ER+/HER2- Advanced Breast Cancer (SIMRISE)
Phase 3
Recruiting
- Conditions
- Locally Advanced or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 460
- Registration Number
- NCT06680921
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Haerbin, Heilongjiang, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Evaluate the Effects of Food on the Pharmacokinetics of SIM0270
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT06536036
- Locations
- 🇨🇳
The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong, China
Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer
Phase 1
Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 214
- Registration Number
- NCT05293964
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath